Clinical Trials

Inclusion Criteria:
1. Patients must be at least 18 years old.
2. Histologically confirmed prostate cancer.
3. Clinical or pathologic stages T1c-T3b, Nx or N0-1, M0-1 (AJCC Criteria 8th Ed.- appendix II).
4. Planned definitive dose radiotherapy to the prostate or prostate bed.
5. ECOG performance status 0-2 (appendix II) assessed within 90 days of enrollment.
6. Patients must sign IRB approved study specific informed consent.
7. Patients must complete all required pre-entry tests listed in section 4.0 within the specified time frames.
8. Patients must be able to start treatment (radiation) within 120 days of study registration.

Exclusion Criteria:
1. Previous pelvic radiation > 5 Gy
2. Planned delivery of radiotherapy to pelvic lymph nodes
3. Planned delivery of brachytherapy of the prostate
4. Active rectal diverticulitis, Crohn’s disease affecting the rectum, or ulcerative colitis (non-active diverticulitis and Crohn’s disease not affecting the rectum are allowed).
5. History of proximal urethral stricture requiring dilatation.
6. Major medical, addictive, or psychiatric illness which in the investigator’s opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (Consent by legal authorized representative is not permitted for this study).           
7. Indwelling or intermittent urinary catheter use

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/4/2024. Questions regarding updates should be directed to the study team contact.